Compare IDEXX Laboratories, Inc. (IDXX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Xylem, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $551.53 (market cap $44.48B), while Xylem, Inc. trades at $118.15 (market cap $28.67B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.43% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | XYL | |
|---|---|---|
Market Cap | $44.48B | $28.67B |
Sector | Health | Industrials |
52-Week High | $766.68 | $152.95 |
52-Week Low | $520.87 | $106.34 |
Enterprise Value | $45.38B | $29.92B |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Xylem (XYL) trades at $120.64, down 1.74% over 24 hours, with a bullish technical signal from moving averages and strong support near $118. The company reported consistent earnings beats, with Q1 2026 EPS of $1.12 exceeding the $1.08 estimate, and revenue growth from $5.5B in 2022 to $9.04B in 2025. Recent developments include a partnership with Gross-Wen Technologies and leadership appointments, reinforcing its position in water solutions.
Outlook remains positive with a consensus price target of $153, implying 27% upside, though risks include execution of growth initiatives and macroeconomic pressures on industrial demand. The stock offers a dividend yield supported by 16 consecutive years of increases, appealing for long-term investors seeking water infrastructure exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
